+ 7 (495) 684-04-00

Tag: SPX

Hydrogen fuel technology companies are reviewed. Biogen stock looks vulnerable as FDA approval of its new Alzheimer drug attracts criticism. Stocks hit highs, but not very convincingly.
SPX gets extremely overbought. Our Core Strategy catches up. A breakout in RUTH is possible.
'Sell in May' critics are running wild this year. Meanwhile, bearish trends are usually strong in the next six months. Historically, these months warrant caution.
To access this post, you must purchase Subscription Plan – AVC Pro.
Closer look at Emerging Markets after last years stellar returns. Barrons Big Money looks bullish from the outside only. SaaS is overvalued still.. Seasonality shifts towards small caps. Financial Vulnerability is a hot topic after COVID.
May is a tricky month. May in post election years are generally positive, and are one of the best months of the year.
To access this post, you must purchase Subscription Plan – AVC Pro.
Last week, the MACD line on the two of the largest and well followed US Indexes rolled over to sell signals. This ends the bullish 6-month period through April.
We count new Billionaires, while Biden sees room to tax. Jim Grant says the Fed is likely to get blind-sided. Seasonality hits a wall.
Low Interest rates, strong USD, Value Stock strength continue to rule market direction. Coinbase debuts at sky-high valuation. SPX hits upper-band of channel. Healthcare, Biotech and Industrials see strength.
April is the best month for Dow stocks. Its still good in post-election years.
To access this post, you must purchase Subscription Plan – AVC Pro.
Seasonality has slightly moved forward this month. Will we see more weakness ahead, as this month's gains are above average already with last week's move from the US stimulus announcement?
To access this post, you must purchase Subscription Plan – AVC Pro.
Scroll to Top